Another focus activity of East Asia Company is POCT rapid diagnostic reagents and related equipment. Having a good collaboration with fast growing POCT leader in China, Genrui Biotech Inc., is specialized in R&D, manufacture and sales of rapid diagnostic reagents and related equipment, East Asia Company is promoting and selling as Agent of Genrui Biotech Inc, rapid tests in Romania and Middle East area.

About Genrui Biotech Inc

Genrui Biotech Inc. (formerly known as “Shenzhen Genius Electronics Co., Ltd”), is one of the leading Chinese companies specialized in developing, manufacturing and marketing IVD equipment and reagents. Established in 2004, Genrui has experienced great progress in both product development and market presence. Product range covers Immunoassay, Chemistry, Hematology, Urinalysis, and Point-of-Care, as well as associated reagents, while market presence spreads across whole of China and more than 100 countries worldwide.


Since December of 2019, several unexplain pneumonia cases ware found in Wuhan, Hubei province of China. The virus has been named “SARS-CoV-2” and the disease it causes has been named “Coronavirus disease 2019” (abbreviated “COVID-19”) by World Health Organization.

Being the “spear” in disease rapid detection, Genrui Biotech Inc. developed a Complete solution for rapid diagnosis.

Genrui COVID-19 IgM/IgG antibody rapid test kit is recommended by Spanish medical authority

The study, conducted by The Health Service of The Balearic Islands (https://www.ibsalut.es/) in Spain, has concluded that COVID-19 IgM/IgG antibody rapid test is important for diagnosis of COVID-19, and that Genrui’s Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Test Kit (Colloidal Gold) is particularly recommended.

The study discussed that, although PCR is currently used as diagnostic technique, it has some deficiencies such as longer turnaround time, more requirements for equipment, reagents and well-trained professionals, etc. Through rapid test, especially IgM/IgG antibody detection, it can make the diagnosis of COVID-19 more economical and comprehensive.

The reliability test of Genrui’s Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Test Kit (Colloidal Gold) was performed in the Hospital Universitario Son Espases (http://www.hospitalsonespases.es/). It comes that Genrui IgM/IgG antibody rapid test is excellent no matter in sensitivity (more than 80%) or specificity (nearly 100%).

Hospital Universitario Son Espases (GHUSE), which has 816 beds and 27 operating rooms, 7 of which are used for emergency treatment. GHUSE, as the autonomous Hospital of Belearic, provides Hospital services for 1047288 local residents, and receives 504800 consultation, 127300 emergency and 19,000 surgical operations a year.

According to the study, Genrui’s Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Test Kit (Colloidal Gold) has been proven to be essential. “For all these reasons, this technique, in particular the product of Genrui Biotech Inc It is considered essential in the diagnostic strategy of the COVID-19 in the Autonomous Community of the Balearic Islands”, said the healthcare director of the Health Service of Balearic Islands.